Search

Search Results

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  592

  PDF: 407

  HTML: 15

• A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

  Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  06-06-2023

  https://doi.org/10.4081/dr.2023.9722

  858

  PDF: 488

  HTML: 27
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1172

  PDF: 577

  HTML: 28

• Papillon-Lefèvre syndrome with excellent response to risankizumab

  Latifah Alibrahim, Sarah Alrashid, Majed Aleissa

  25-02-2026

  https://doi.org/10.4081/dr.2026.10309

  362

  PDF: 350

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  1097

  PDF: 581

  SUPPLEMENTARY MATERIAL: 189

  HTML: 24

• Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

  Paolo Dapavo, Matteo Megna, Marina Talamonti

  09-08-2024

  https://doi.org/10.4081/dr.2024.9999

  1866

  PDF: 766

  HTML: 109

• Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

  Karan Rajalingam, Phillip M. Johansen, Nicole J. Levin, Jerry Qi, Oge Marques

  11-09-2023

  https://doi.org/10.4081/dr.2023.9824

  1015

  PDF: 979

  HTML: 41

• Efficacy of a topical polyphenol-based formulation in palmoplantar psoriasis: an observational study

  Simone Amato, Annunziata Dattola, Luigi Bennardo, Martina Tolone, Steven Paul Nisticò

  08-07-2025

  https://doi.org/10.4081/dr.2025.10333

  564

  PDF: 381

  HTML: 44

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  521

  PDF: 331

  HTML: 27

• Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors

  Anna Paola Lugli, Niccolò Gori, Elena Ippoliti, Benedetta Ambrosio, Ketty Peris

  03-02-2026

  https://doi.org/10.4081/dr.2026.10644

  785

  PDF: 523
• 

  Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

  Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

  25-06-2020

  https://doi.org/10.4081/dr.2020.8642

  1425

  PDF: 776

  HTML: 19